Neutralizing Antibody to Omicron BA.1, BA.2 and BA.5 in COVID-19 Patients

Susanne L. Linderman, Lilin Lai, Estefany L. Bocangel Gamarra, Nicholas M. Mohr, Kevin W. Gibbs, Jay S. Steingrub, Matthew C. Exline, Nathan I. Shapiro, Anne Frosch, Nida Qadir, Srilatha Edupuganti, Diya Surie, Mark W. Tenforde, Meredith E. Davis-Gardner, James D. Chappell, Max S. Y. Lau, M. Juliana McElrath, Adam S. Lauring, Mehul S. Suthar, Manish M. Patel, Wesley H. Self, Rafi AhmedmedRxiv 2022 · DOI

This study, published as a preprint in August 2022, provides a detailed look at how our immune systems "see" different versions of the SARS-CoV-2 virus depending on our prior exposure. By comparing patients infected with the Delta variant versus those infected with Omicron (BA.1/BA.2), the researchers demonstrate that Omicron infections trigger a much broader and more balanced antibody response than Delta, though even an Omicron infection doesn't provide perfect coverage against the then-emerging BA.5 subvariant.

TL;DR

Researchers analyzed how hospitalized COVID-19 patients neutralize different variants, finding that Delta infections produce a narrow immune response, while Omicron infections generate antibodies that are better at "cross-recognizing" multiple strains. However, because neutralization of the BA.5 subvariant remained significantly lower across the board, the study concludes that including BA.5 in updated vaccines is a necessary step for robust protection.

What Problem Does This Paper Address?

As SARS-CoV-2 continues to evolve, a major concern in immunology is "imprinting" (sometimes called Original Antigenic Sin). This is the idea that our first exposure to a virus—either through vaccination or infection—shapes our immune response so strongly that it becomes difficult for the body to "learn" how to fight new, significantly different variants.

The authors sought to determine if infection with the highly mutated Omicron variant could overcome this imprinting. Specifically, they wanted to know if an Omicron infection (in both vaccinated and unvaccinated people) produces a "balanced" response that covers both the original strain and newer variants, or if the immune system remains stuck in the past.

Methods

The team used a Live Virus Neutralization Assay, specifically a Focus Reduction Neutralization Test (FRNT50).

  • The Process: They took serum (the antibody-rich part of the blood) from 187 patients and mixed it with live samples of five different SARS-CoV-2 variants: WA1 (the ancestral 2020 strain), Delta, BA.1, BA.2, and BA.5.
  • The Metric: They measured the "titer"—the degree to which the serum could be diluted while still successfully blocking 50% of the virus from infecting cells in a lab dish.
  • Novelty: Unlike many studies that use "pseudoviruses" (harmless viruses engineered to look like SARS-CoV-2), this study used authentic live virus isolates, which is considered the gold standard for measuring neutralizing capacity.

Datasets

The study utilized a clinical cohort of 187 hospitalized adult patients enrolled through the IVY Network (a CDC-collaboration across 8 U.S. hospitals) between July 2021 and March 2022.

  • Patient Breakdown: 80 unvaccinated and 107 vaccinated (mostly mRNA vaccines).
  • Variant Confirmation: 69% of cases were sequence-confirmed as Delta or Omicron; the rest were classified based on the dominant variant circulating at the time of their hospitalization.
  • Comparison Groups: The researchers specifically looked at "Unvaccinated Delta," "Vaccinated Delta," "Unvaccinated Omicron," and "Vaccinated Omicron" cohorts.

Key Insights and Ideas

  • Delta Infection is "Narrow": Unvaccinated patients infected with Delta produced antibodies that were great at killing Delta but terrible at killing Omicron (60-fold lower effectiveness). Their immune system focused almost entirely on the specific shape of the Delta spike protein.
  • Vaccination Acts as a Buffer: In vaccinated patients who then caught Delta, the response was more even between the original WA1 strain and Delta. This suggests the vaccine "primed" the memory B cells to recognize features common to both.
  • Omicron is an Immune "Generalist": Surprisingly, patients infected with Omicron (BA.1 or BA.2) showed a much more "balanced" ratio. Their antibodies could neutralize the ancestral WA1 strain and the Omicron variants with similar efficiency. This suggests that Omicron infection might broaden the immune repertoire more effectively than previous variants.
  • The BA.5 Gap: Even though Omicron-infected patients had a broader response, their ability to neutralize the BA.5 subvariant was still 3 to 4 times lower than their ability to neutralize BA.1. This "drop-off" provided the empirical evidence needed to support the transition to BA.5-specific bivalent vaccines.

Key Results

  • Geometric Mean Titers (GMT): In unvaccinated Delta patients, the GMT for Delta was 1093, but plummeted to just 18 for BA.1.
  • The Ratio Shift: The ratio of BA.1-to-WA1 neutralization was 10 to 19 times higher in Omicron-infected patients compared to Delta-infected patients.
  • BA.5 Vulnerability: In vaccinated Omicron patients, the GMT for BA.1 was 128, while for BA.5 it was only 60. This quantitative gap highlights why BA.5 was able to cause significant breakthrough infections even in people who had recently recovered from BA.1.

Limitations and Future Work

  • Severity Bias: The study focused on hospitalized patients. These individuals likely had high viral loads and severe symptoms, which typically trigger a much stronger (and potentially different) antibody response than mild or asymptomatic cases.
  • Single Exposure vs. Hybrid Immunity: Most patients were analyzed after a single infection. The paper does not fully explore the "layering" effect of multiple infections with different variants over time.
  • Vaccine Translation: The authors caution that while infection with Omicron produces a balanced response, a single vaccine dose of an Omicron-specific booster might not do the same. They suggest two doses of an updated vaccine might be necessary to properly "prime" the immune system to the new variant's features.

Summary updated

Abstract

Abstract Neutralizing antibody plays a key role in protective immunity against COVID-19. As increasingly distinct variants circulate, debate continues regarding the value of adding novel variants to SARS-CoV-2 vaccines. In this study, we have analyzed live virus neutralization titers against WA1, Delta, BA.1, BA.2, and BA.5 in 187 hospitalized patients infected with Delta or Omicron strains. This information will be useful in selection of the SARS-CoV-2 strains to include in an updated vaccine. Our results show that unvaccinated Delta infected patients made a highly biased neutralizing antibody response towards the infecting Delta strain with slightly lower responses against the WA1 strain, but with strikingly lower titers against BA.1, BA.2, and BA.5. Delta infected patients that had been previously vaccinated with the WA1 containing COVID vaccine made equivalent responses to WA1 and Delta strains, but still had very low neutralizing antibody responses to Omicron strains. In striking contrast, both unvaccinated and vaccinated Omicron patients exhibited a more balanced ratio of Omicron virus neutralization compared to neutralization of ancestral strains. Interestingly, Omicron patients infected with BA.1 or BA.2 had detectable neutralizing antibody titers to BA.5, but these titers were lower than neutralization titers to BA.1 and BA.2. Taken together, these results suggest that inclusion of the Omicron BA.5 strain in a SARS-CoV-2 vaccine would be beneficial in protection against the widely circulating BA.5 variant. Disclaimer The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
BibTeX
@misc{linderman2022neutralizing,
  author = {Susanne L. Linderman and Lilin Lai and Estefany L. Bocangel Gamarra and Nicholas M. Mohr and Kevin W. Gibbs and Jay S. Steingrub and Matthew C. Exline and Nathan I. Shapiro and Anne Frosch and Nida Qadir and Srilatha Edupuganti and Diya Surie and Mark W. Tenforde and Meredith E. Davis-Gardner and James D. Chappell and Max S. Y. Lau and M. Juliana McElrath and Adam S. Lauring and Mehul S. Suthar and Manish M. Patel and Wesley H. Self and Rafi Ahmed},
  title = {{Neutralizing Antibody to Omicron BA.1, BA.2 and BA.5 in COVID-19 Patients}},
  year = {2022},
  doi = {10.1101/2022.08.21.22278552},
  howpublished = {medRxiv},
}
Figure